Enorama Pharma AB (publ) (ERMA.ST)

SEK 2.7

(0.75%)

Total Liabilities Summary of Enorama Pharma AB (publ)

Enorama Pharma AB (publ)'s latest annual total liabilities in 2023 was 14.84 Million SEK , down -13.67% from previous year.
Enorama Pharma AB (publ)'s latest quarterly total liabilities in 2024 Q1 was 17.24 Million SEK , up 16.18% from previous quarter.
Enorama Pharma AB (publ) reported annual total liabilities of 17.19 Million SEK in 2022, down -41.86% from previous year.
Enorama Pharma AB (publ) reported annual total liabilities of 29.57 Million SEK in 2021, down -24.4% from previous year.
Enorama Pharma AB (publ) reported quarterly total liabilities of 17.24 Million SEK for 2024 Q1, up 16.18% from previous quarter.
Enorama Pharma AB (publ) reported quarterly total liabilities of 14.84 Million SEK for 2023 FY, down -13.67% from previous quarter.

Annual Total Liabilities Chart of Enorama Pharma AB (publ) (2023 - 2014)

Historical Annual Total Liabilities of Enorama Pharma AB (publ) (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	14.84 Million SEK	-13.67%
2022	17.19 Million SEK	-41.86%
2021	29.57 Million SEK	-24.4%
2020	39.12 Million SEK	10.52%
2019	35.4 Million SEK	62.33%
2018	21.81 Million SEK	168.41%
2017	8.12 Million SEK	78.73%
2016	4.54 Million SEK	71.95%
2015	2.64 Million SEK	155.71%
2014	1.03 Million SEK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	10.96 Million SEK	-36.43%
2024 Q1	17.24 Million SEK	16.18%
2023 FY	14.84 Million SEK	-13.67%
2023 Q3	17.57 Million SEK	-14.93%
2023 Q4	14.84 Million SEK	-15.5%
2023 Q2	20.65 Million SEK	43.74%
2023 Q1	14.36 Million SEK	-16.44%
2022 FY	17.19 Million SEK	-41.86%
2022 Q4	17.19 Million SEK	-66.74%
2022 Q3	51.69 Million SEK	-5.12%
2022 Q2	54.48 Million SEK	66.17%
2022 Q1	32.79 Million SEK	10.86%
2021 Q2	39.75 Million SEK	-12.53%
2021 Q1	45.44 Million SEK	16.14%
2021 Q4	29.57 Million SEK	-25.01%
2021 Q3	39.44 Million SEK	-0.78%
2021 FY	29.57 Million SEK	-24.4%
2020 Q1	33.44 Million SEK	-5.54%
2020 Q4	39.12 Million SEK	6.31%
2020 Q3	36.8 Million SEK	-0.99%
2020 Q2	37.17 Million SEK	11.15%
2020 FY	39.12 Million SEK	10.52%
2019 Q4	35.4 Million SEK	82.02%
2019 Q3	19.45 Million SEK	-1.38%
2019 Q2	19.72 Million SEK	34.25%
2019 Q1	14.69 Million SEK	-32.64%
2019 FY	35.4 Million SEK	62.33%
2018 Q3	17.46 Million SEK	-20.95%
2018 Q2	22.08 Million SEK	38.77%
2018 FY	21.81 Million SEK	168.41%
2018 Q4	21.81 Million SEK	24.92%
2018 Q1	15.91 Million SEK	95.88%
2017 Q4	8.12 Million SEK	-28.42%
2017 Q2	11.79 Million SEK	153.37%
2017 Q1	4.65 Million SEK	2.37%
2017 FY	8.12 Million SEK	78.73%
2017 Q3	11.35 Million SEK	-3.72%
2016 FY	4.54 Million SEK	71.95%
2016 Q2	7.17 Million SEK	201.77%
2016 Q4	4.54 Million SEK	-13.42%
2016 Q1	2.37 Million SEK	-10.14%
2016 Q3	5.25 Million SEK	-26.76%
2015 Q4	2.64 Million SEK	0.0%
2015 Q1	- SEK	0.0%
2015 FY	2.64 Million SEK	155.71%
2014 FY	1.03 Million SEK	0.0%

Peer Total Liabilities Comparison of Enorama Pharma AB (publ)

Name	Total Liabilities	Total Liabilities Difference
AcuCort AB	10.97 Million SEK	-35.28%
AlzeCure Pharma AB (publ)	8.22 Million SEK	-80.467%
BioGaia AB (publ)	302.84 Million SEK	95.097%
Enzymatica AB (publ)	49.3 Million SEK	69.886%
Gabather AB (publ)	6.87 Million SEK	-115.862%
Klaria Pharma Holding AB (publ.)	31.98 Million SEK	53.583%
Moberg Pharma AB (publ)	24 Million SEK	38.156%
Nanexa AB (publ)	36.42 Million SEK	59.242%
Newbury Pharmaceuticals AB (publ)	38.95 Million SEK	61.886%
ODI Pharma AB	10.05 Million SEK	-47.619%
Orexo AB (publ)	727.7 Million SEK	97.96%
Probi AB (publ)	181.31 Million SEK	91.812%
Swedencare AB (publ)	2.31 Billion SEK	99.359%
Swedish Orphan Biovitrum AB (publ)	40.16 Billion SEK	99.963%
Toleranzia AB	6.9 Million SEK	-114.894%
Vivesto AB	30.45 Million SEK	51.245%